Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 418

1.

Precision Medicine in Lymphoma by Innovative Instrumental Platforms.

Di Paolo A, Arrigoni E, Luci G, Cucchiara F, Danesi R, Galimberti S.

Front Oncol. 2019 Dec 17;9:1417. doi: 10.3389/fonc.2019.01417. eCollection 2019. Review.

2.

Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment.

Del Re M, Addeo A, Passaro A, Petrini I, van Schaik RH, Danesi R.

Pharmacogenomics. 2019 Dec;20(18):1255-1257. doi: 10.2217/pgs-2019-0150. No abstract available.

PMID:
31829835
3.

Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.

Del Re M, Petrini I, Mazzoni F, Valleggi S, Gianfilippo G, Pozzessere D, Chella A, Crucitta S, Rofi E, Restante G, Miccoli M, Garassino MC, Danesi R.

Clin Lung Cancer. 2019 Oct 13. pii: S1525-7304(19)30268-2. doi: 10.1016/j.cllc.2019.10.003. [Epub ahead of print]

PMID:
31735523
4.

Corrigendum to "Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors" [Cancer Treatm. Rev. 74 (2019) 21-28].

Fogli S, Del Re M, Curigliano G, van Schaik RH, Lancellotti P, Danesi R.

Cancer Treat Rev. 2019 Dec;81:101913. doi: 10.1016/j.ctrv.2019.101913. Epub 2019 Nov 6. No abstract available.

PMID:
31706687
5.

Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers.

Rofi E, Del Re M, Arrigoni E, Rizzo M, Fontanelli L, Crucitta S, Gianfilippo G, Restante G, Fogli S, Porta C, Danesi R, Schmidinger M.

Crit Rev Oncol Hematol. 2019 Dec;144:102812. doi: 10.1016/j.critrevonc.2019.09.004. Epub 2019 Sep 26. Review.

PMID:
31698313
6.

Circulating biomarkers of response to immunotherapy in cancer treatment.

Del Re M, Gianfilippo G, Crucitta S, Addeo A, van Schaik RH, Danesi R.

Pharmacogenomics. 2019 Dec;20(18):1247-1249. doi: 10.2217/pgs-2019-0117. Epub 2019 Nov 6. No abstract available.

7.

Identification of a novel large EPCAM-MSH2 duplication, concurrently with LOHs in chromosome 20 and X, in a family with Lynch syndrome.

Pirini F, Tedaldi G, Danesi R, Cangini I, Tumedei MM, Ferrari A, Vitali S, De Maio G, Terragna C, Solli V, Tebaldi M, Puccetti M, Zampiga V, Ravegnani M, Ulivi P, Falcini F, Martinelli G, Calistri D.

Int J Colorectal Dis. 2019 Nov;34(11):1999-2002. doi: 10.1007/s00384-019-03414-y. Epub 2019 Oct 26.

PMID:
31655866
8.

Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy.

Crucitta S, Restante G, Del Re M, Bertolini I, Bona E, Rofi E, Fontanelli L, Gianfilippo G, Fogli S, Stasi I, Ghilli M, Fontana A, Danesi R.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1219-1227. doi: 10.1007/s00280-019-03933-z. Epub 2019 Sep 16.

PMID:
31529205
9.

Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition.

Tedaldi G, Pirini F, Tebaldi M, Zampiga V, Cangini I, Danesi R, Arcangeli V, Ravegnani M, Abou Khouzam R, Molinari C, Oliveira C, Morgagni P, Saragoni L, Bencivenga M, Ulivi P, Amadori D, Martinelli G, Falcini F, Ranzani GN, Calistri D.

Cancers (Basel). 2019 Sep 11;11(9). pii: E1340. doi: 10.3390/cancers11091340.

10.

Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.

Pasqualetti F, Restante G, Gonnelli A, Rofi E, Molinari A, Crucitta S, Paiar F, Rudà R, Danesi R, Soffietti R, Del Re M.

Neuro Oncol. 2019 Dec 17;21(12):1610-1611. doi: 10.1093/neuonc/noz157. No abstract available.

PMID:
31504796
11.

Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy.

Del Re M, Crucitta S, Gianfilippo G, Passaro A, Petrini I, Restante G, Michelucci A, Fogli S, de Marinis F, Porta C, Chella A, Danesi R.

Int J Mol Sci. 2019 Aug 14;20(16). pii: E3951. doi: 10.3390/ijms20163951. Review.

12.

Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.

Del Re M, Bertolini I, Crucitta S, Fontanelli L, Rofi E, De Angelis C, Diodati L, Cavallero D, Gianfilippo G, Salvadori B, Fogli S, Falcone A, Scatena C, Naccarato AG, Roncella M, Ghilli M, Morganti R, Fontana A, Danesi R.

Breast Cancer Res Treat. 2019 Nov;178(1):57-62. doi: 10.1007/s10549-019-05365-y. Epub 2019 Jul 26.

PMID:
31346846
13.

Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.

Rimassa L, Danesi R, Pressiani T, Merle P.

Cancer Treat Rev. 2019 Jul;77:20-28. doi: 10.1016/j.ctrv.2019.05.004. Epub 2019 May 15. Review.

14.

Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time.

Sarli V, Ciofi L, Lastella M, Muscatello B, Pisaturo F, Paolilli O, Luci G, Cucchiara F, Pellegrini G, Bocci G, Danesi R, Di Paolo A.

Clin Chem Lab Med. 2019 Nov 26;57(12):e331-e333. doi: 10.1515/cclm-2019-0429. No abstract available.

PMID:
31188753
15.

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.

Cazzaniga ME, Danesi R, Girmenia C, Invernizzi P, Elvevi A, Uguccioni M; NetworkER+.

Breast Cancer Res Treat. 2019 Aug;176(3):483-494. doi: 10.1007/s10549-019-05261-5. Epub 2019 May 7. Review.

16.

AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer.

Del Re M, Crucitta S, Sbrana A, Rofi E, Paolieri F, Gianfilippo G, Galli L, Falcone A, Morganti R, Porta C, Efstathiou E, van Schaik R, Jenster G, Danesi R.

BJU Int. 2019 May 4. doi: 10.1111/bju.14792. [Epub ahead of print]

PMID:
31055861
17.

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report.

Del Re M, Rofi E, Cappelli C, Puppo G, Crucitta S, Valeggi S, Chella A, Danesi R, Petrini I.

BMC Cancer. 2019 Apr 30;19(1):410. doi: 10.1186/s12885-019-5604-6.

18.

From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.

Bordi P, Del Re M, Minari R, Rofi E, Buti S, Restante G, Squadrilli A, Crucitta S, Casartelli C, Gnetti L, Azzoni C, Bottarelli L, Petrini I, Cosenza A, Ferri L, Rapacchi E, Danesi R, Tiseo M.

Lung Cancer. 2019 May;131:78-85. doi: 10.1016/j.lungcan.2019.03.017. Epub 2019 Mar 19.

PMID:
31027702
19.

Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence.

Macera L, Spezia PG, Medici C, Rofi E, Del Re M, Focosi D, Mazzetti P, Navarro D, Antonelli G, Danesi R, Pistello M, Maggi F.

J Med Virol. 2019 Apr 19. doi: 10.1002/jmv.25488. [Epub ahead of print]

PMID:
31002743
20.

Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes.

Allegra S, Di Paolo A, Cusato J, Fatiguso G, Arrigoni E, Danesi R, Corcione S, DʼAvolio A.

Ther Drug Monit. 2019 Apr;41(2):254-255. doi: 10.1097/FTD.0000000000000596. No abstract available.

PMID:
30883522
21.

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.

Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremolini C, Crucitta S, Barbara C, Di Leo A, Latiano TP, Pietrantonio F, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R.

Pharmacogenomics J. 2019 Dec;19(6):556-563. doi: 10.1038/s41397-019-0077-1. Epub 2019 Feb 6.

22.

Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors.

Fogli S, Del Re M, Curigliano G, van Schaik RH, Lancellotti P, Danesi R.

Cancer Treat Rev. 2019 Mar;74:21-28. doi: 10.1016/j.ctrv.2019.01.006. Epub 2019 Jan 19. Review. Erratum in: Cancer Treat Rev. 2019 Dec;81:101913.

23.

Rebuttal letter: Different underlying mechanism might explain the absence of a significant difference in AUC of linezolid for different ABCB1 genotypes.

Allegra S, Di Paolo A, Cusato J, Fatiguso G, Arrigoni E, Danesi R, Corcione S, DʼAvolio A.

Ther Drug Monit. 2019 Jan 9. doi: 10.1097/FTD.0000000000000596. [Epub ahead of print] No abstract available.

PMID:
30633091
24.

The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer.

Rofi E, Vivaldi C, Del Re M, Arrigoni E, Crucitta S, Funel N, Fogli S, Vasile E, Musettini G, Fornaro L, Falcone A, Danesi R.

Pharmacogenomics. 2019 Jan;20(1):49-68. doi: 10.2217/pgs-2018-0149. Epub 2018 Dec 6.

PMID:
30520336
25.

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.

Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D.

JAMA Oncol. 2019 Mar 1;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080.

26.

Radiomics and liquid biopsy in oncology: the holons of systems medicine.

Neri E, Del Re M, Paiar F, Erba P, Cocuzza P, Regge D, Danesi R.

Insights Imaging. 2018 Dec;9(6):915-924. doi: 10.1007/s13244-018-0657-7. Epub 2018 Nov 14. Review.

27.

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.

Del Re M, Bordi P, Rofi E, Restante G, Valleggi S, Minari R, Crucitta S, Arrigoni E, Chella A, Morganti R, Tiseo M, Petrini I, Danesi R.

Br J Cancer. 2018 Nov;119(10):1252-1258. doi: 10.1038/s41416-018-0238-z. Epub 2018 Nov 6.

28.

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.

Cuneo A, Barosi G, Danesi R, Fagiuoli S, Ghia P, Marzano A, Montillo M, Poletti V, Viale P, Zinzani PL.

Hematol Oncol. 2019 Feb;37(1):3-14. doi: 10.1002/hon.2540. Epub 2018 Sep 5. Review.

29.

The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review.

Matucci A, Vultaggio A, Danesi R.

Respir Res. 2018 Aug 16;19(1):154. doi: 10.1186/s12931-018-0859-z. Review.

30.

Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position.

Ciccolini J, Del Re M, Danesi R, Milano G, Schellens JHM, Raymond E.

Ann Oncol. 2018 Sep 1;29(9):1893-1894. doi: 10.1093/annonc/mdy258. No abstract available.

31.

A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance.

Allegra S, Di Paolo A, Cusato J, Fatiguso G, Arrigoni E, Danesi R, Corcione S, DʼAvolio A.

Ther Drug Monit. 2018 Oct;40(5):602-609. doi: 10.1097/FTD.0000000000000536.

PMID:
29979333
32.

EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance.

Fogli S, Polini B, Del Re M, Petrini I, Passaro A, Crucitta S, Rofi E, Danesi R.

Pharmacogenomics. 2018 Jun 1;19(8):727-740. doi: 10.2217/pgs-2018-0038. Epub 2018 May 22. Review.

PMID:
29785875
33.

Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.

Del Re M, Crucitta S, Restante G, Rofi E, Arrigoni E, Biasco E, Sbrana A, Coppi E, Galli L, Bracarda S, Santini D, Danesi R.

Crit Rev Oncol Hematol. 2018 May;125:51-59. doi: 10.1016/j.critrevonc.2018.03.002. Epub 2018 Mar 6. Review.

PMID:
29650277
34.

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.

Del Re M, Marconcini R, Pasquini G, Rofi E, Vivaldi C, Bloise F, Restante G, Arrigoni E, Caparello C, Bianco MG, Crucitta S, Petrini I, Vasile E, Falcone A, Danesi R.

Br J Cancer. 2018 Mar 20;118(6):820-824. doi: 10.1038/bjc.2018.9. Epub 2018 Mar 6.

35.

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.

Cremolini C, Del Re M, Antoniotti C, Lonardi S, Bergamo F, Loupakis F, Borelli B, Marmorino F, Citi V, Cortesi E, Moretto R, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Ricci V, Di Donato S, Zagonel V, Boni L, Falcone A, Danesi R.

Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30.

36.

Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.

Citi V, Del Re M, Martelli A, Calderone V, Breschi MC, Danesi R.

Cancer Chemother Pharmacol. 2018 Apr;81(4):745-754. doi: 10.1007/s00280-018-3543-6. Epub 2018 Feb 23.

PMID:
29476223
37.

Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

Del Re M, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, Di Maio M, Petrini I, Danesi R.

Oncotarget. 2017 Dec 21;9(5):6630-6643. doi: 10.18632/oncotarget.23553. eCollection 2018 Jan 19. Review.

38.

Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment.

Arrigoni E, Del Re M, Galimberti S, Restante G, Rofi E, Crucitta S, Baratè C, Petrini M, Danesi R, Di Paolo A.

Stem Cells Transl Med. 2018 Mar;7(3):305-314. doi: 10.1002/sctm.17-0175. Epub 2018 Feb 8. Review.

39.

Clinical pharmacology of intravitreal anti-VEGF drugs.

Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R.

Eye (Lond). 2018 Jun;32(6):1010-1020. doi: 10.1038/s41433-018-0021-7. Epub 2018 Feb 5. Review.

40.

Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells.

Del Re M, Arrigoni E, Restante G, Passaro A, Rofi E, Crucitta S, De Marinis F, Di Paolo A, Danesi R.

Stem Cells. 2018 May;36(5):633-640. doi: 10.1002/stem.2787. Epub 2018 Feb 5. Review.

41.

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.

Minari R, Bordi P, Del Re M, Facchinetti F, Mazzoni F, Barbieri F, Camerini A, Comin CE, Gnetti L, Azzoni C, Nizzoli R, Bortesi B, Rofi E, Petreni P, Campanini N, Rossi G, Danesi R, Tiseo M.

Lung Cancer. 2018 Jan;115:21-27. doi: 10.1016/j.lungcan.2017.11.011. Epub 2017 Nov 13.

PMID:
29290257
42.

Individualized dosing with axitinib: rationale and practical guidance.

Schmidinger M, Danesi R, Jones R, McDermott R, Pyle L, Rini B, Négrier S.

Future Oncol. 2018 Apr;14(9):861-875. doi: 10.2217/fon-2017-0455. Epub 2017 Dec 21. Review.

43.

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.

Del Re M, Bordi P, Petrini I, Rofi E, Mazzoni F, Belluomini L, Vasile E, Restante G, Di Costanzo F, Falcone A, Frassoldati A, van Schaik RHN, Steendam CMJ, Chella A, Tiseo M, Morganti R, Danesi R.

Oncotarget. 2017 Sep 15;8(49):86056-86065. doi: 10.18632/oncotarget.20947. eCollection 2017 Oct 17.

44.

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.

Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A.

Oncotarget. 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20.

45.

Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.

Schmidinger M, Danesi R.

Oncologist. 2018 Mar;23(3):306-315. doi: 10.1634/theoncologist.2017-0335. Epub 2017 Nov 16. Review.

46.

Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.

Matrone A, Valerio L, Pieruzzi L, Giani C, Cappagli V, Lorusso L, Agate L, Puleo L, Viola D, Bottici V, Del Re M, Molinaro E, Danesi R, Elisei R.

Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):319-334. doi: 10.1016/j.beem.2017.06.001. Epub 2017 Jun 15. Review.

PMID:
28911728
47.

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule.

Di Paolo A, Bracarda S, Arrigoni E, Danesi R.

Front Pharmacol. 2017 Aug 7;8:523. doi: 10.3389/fphar.2017.00523. eCollection 2017. No abstract available.

48.

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer.

Del Re M, Vivaldi C, Rofi E, Vasile E, Miccoli M, Caparello C, d'Arienzo PD, Fornaro L, Falcone A, Danesi R.

Sci Rep. 2017 Aug 11;7(1):7931. doi: 10.1038/s41598-017-08297-z.

49.

Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.

Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R.

Eur Urol. 2018 Jan;73(1):e11-e12. doi: 10.1016/j.eururo.2017.07.034. Epub 2017 Aug 9. No abstract available.

PMID:
28801127
50.

Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Ardizzoni A, Barberis M, Cappuzzo F, Casaluce F, Danesi R, Troncone G, De Marinis F.

Transl Lung Cancer Res. 2017 Jun;6(3):373-386. doi: 10.21037/tlcr.2017.05.09. Review.

Supplemental Content

Loading ...
Support Center